Case Studies

Challenge: Anti-nerve growth factor inhibitors are a new class of powerful analgesics in clinical development. They were put on clinical development hold by the FDA in 2012 due to joint-related...

Challenge: The technology transfer function of a leading cancer research institute needed a development plan for a promising small molecule lead series against a novel anti-invasion/anti-metastasis...

Challenge: A US medical device company wanted to understand how UK payers would view their technology. They engaged Alacrita to find out.

Challenge: A major European venture capital investor needed help to review the business plan and competitive positioning of a novel point-of-care diagnostics company. The company was developing a...

Challenge: A leading cancer research charity needed project management and drug development expertise to shepherd two preclinical programs into Phase I/II clinical trials. Alacrita was engaged to...

Challenge: After a seed investment, a startup biotech had built an IP portfolio in the field of glucosinolates, chemicals found in brassica vegetables, that are potent inducers of cytoprotective...

Alacrita is a leading provider of due diligence to the pharmaceutical industry. Its core team of partners, each of whom has industry experience, are supported by a team of expert, life science...